SCHEMBL20138449

SCHEMBL20138449

CC(c1ccc(OC(F)F)cc1)n1nc(COCc2ccccc2)c(C(N)=O)c1N

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.67
HSD11B1 P28845 2/20 0.38
RET P07949 1/20 0.36
ALOX5 P09917 1/20 0.36
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
GPR139 Q6DWJ6 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GRM2 Q14416 1/20 0.34
POLB P06746 1/20 0.34
DAGLA Q9Y4D2 1/20 0.34
XIAP P98170 1/20 0.34
CYP3A4 P08684 1/20 0.34
GHSR Q92847 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20581431 0.88 PDE2A (0.74) PDE2ARETALOX5XIAPGHSR
SCHEMBL20138434 0.88 PDE2A (0.71) PDE2APLA2G10PLA2G2A
SCHEMBL18283117 0.87 PDE2A (0.69) PDE2ARETALOX5L3MBTL1POLB
SCHEMBL18282926 0.86 PDE2A (0.76) PDE2ARETGHSR
SCHEMBL18291819 0.86 PDE2A (0.49) PDE2AHSD11B1GPR139L3MBTL1CYP3A4
SCHEMBL20138441 0.85 PDE2A (0.69) PDE2ARETLMNAXIAPGHSR
SCHEMBL20138450 0.84 PDE2A (0.71) PDE2ARETALOX5LMNAXIAP
SCHEMBL20150753 0.84 PDE2A (0.46) PDE2AHSD11B1RETGPR139L3MBTL1
SCHEMBL18283165 0.84 PDE2A (0.65) PDE2ARETXIAPGHSR
SCHEMBL20202562 0.82 PDE2A (0.79) PDE2ARETGPR139MRGPRX4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302484-B1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-09-16 EP disclosed
EP-3302484-B1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-09-16 EP disclosed
US-10160762-B2 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2018-12-25 US disclosed
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-17 US disclosed
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160762-B2 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D PDE2A 2/4885HSD11B1 591/4885RET 2086/4885
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D PDE2A 2/4885HSD11B1 591/4885RET 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.